Cargando…
The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line
In recent years, there has been a significant increase in the registration of drugs for nasal application with systemic effects. Previous preclinical in vitro test systems for transmucosal drug absorption studies have mostly been based on primary cells or on tumor cell lines such as RPMI 2650, but b...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536430/ https://www.ncbi.nlm.nih.gov/pubmed/37765214 http://dx.doi.org/10.3390/pharmaceutics15092245 |
_version_ | 1785112863722962944 |
---|---|
author | Bendas, Sebastian Koch, Eugen Viktor Nehlsen, Kristina May, Tobias Dietzel, Andreas Reichl, Stephan |
author_facet | Bendas, Sebastian Koch, Eugen Viktor Nehlsen, Kristina May, Tobias Dietzel, Andreas Reichl, Stephan |
author_sort | Bendas, Sebastian |
collection | PubMed |
description | In recent years, there has been a significant increase in the registration of drugs for nasal application with systemic effects. Previous preclinical in vitro test systems for transmucosal drug absorption studies have mostly been based on primary cells or on tumor cell lines such as RPMI 2650, but both approaches have disadvantages. Therefore, the aim of this study was to establish and characterize a novel immortalized nasal epithelial cell line as the basis for an improved 3D cell culture model of the nasal mucosa. First, porcine primary cells were isolated and transfected. The P1 cell line obtained from this process was characterized in terms of its expression of tissue-specific properties, namely, mucus expression, cilia formation, and epithelial barrier formation. Using air–liquid interface cultivation, it was possible to achieve both high mucus formation and the development of functional cilia. Epithelial integrity was expressed as both transepithelial electrical resistance and mucosal permeability, which was determined for sodium fluorescein, rhodamine B, and FITC-dextran 4000. We noted a high comparability of the novel cell culture model with native excised nasal mucosa in terms of these measures. Thus, this novel cell line seems to offer a promising approach for developing 3D nasal mucosa tissues that exhibit favorable characteristics to be used as an in vitro system for testing drug delivery systems. |
format | Online Article Text |
id | pubmed-10536430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105364302023-09-29 The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line Bendas, Sebastian Koch, Eugen Viktor Nehlsen, Kristina May, Tobias Dietzel, Andreas Reichl, Stephan Pharmaceutics Article In recent years, there has been a significant increase in the registration of drugs for nasal application with systemic effects. Previous preclinical in vitro test systems for transmucosal drug absorption studies have mostly been based on primary cells or on tumor cell lines such as RPMI 2650, but both approaches have disadvantages. Therefore, the aim of this study was to establish and characterize a novel immortalized nasal epithelial cell line as the basis for an improved 3D cell culture model of the nasal mucosa. First, porcine primary cells were isolated and transfected. The P1 cell line obtained from this process was characterized in terms of its expression of tissue-specific properties, namely, mucus expression, cilia formation, and epithelial barrier formation. Using air–liquid interface cultivation, it was possible to achieve both high mucus formation and the development of functional cilia. Epithelial integrity was expressed as both transepithelial electrical resistance and mucosal permeability, which was determined for sodium fluorescein, rhodamine B, and FITC-dextran 4000. We noted a high comparability of the novel cell culture model with native excised nasal mucosa in terms of these measures. Thus, this novel cell line seems to offer a promising approach for developing 3D nasal mucosa tissues that exhibit favorable characteristics to be used as an in vitro system for testing drug delivery systems. MDPI 2023-08-30 /pmc/articles/PMC10536430/ /pubmed/37765214 http://dx.doi.org/10.3390/pharmaceutics15092245 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bendas, Sebastian Koch, Eugen Viktor Nehlsen, Kristina May, Tobias Dietzel, Andreas Reichl, Stephan The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line |
title | The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line |
title_full | The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line |
title_fullStr | The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line |
title_full_unstemmed | The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line |
title_short | The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 1—Establishing a Nasal In Vitro Model for Drug Delivery Testing Based on a Novel Cell Line |
title_sort | path from nasal tissue to nasal mucosa on chip: part 1—establishing a nasal in vitro model for drug delivery testing based on a novel cell line |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536430/ https://www.ncbi.nlm.nih.gov/pubmed/37765214 http://dx.doi.org/10.3390/pharmaceutics15092245 |
work_keys_str_mv | AT bendassebastian thepathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT kocheugenviktor thepathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT nehlsenkristina thepathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT maytobias thepathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT dietzelandreas thepathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT reichlstephan thepathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT bendassebastian pathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT kocheugenviktor pathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT nehlsenkristina pathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT maytobias pathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT dietzelandreas pathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline AT reichlstephan pathfromnasaltissuetonasalmucosaonchippart1establishinganasalinvitromodelfordrugdeliverytestingbasedonanovelcellline |